Anesthetic management of patients with coronary artery disease remains an important clinical problem. The long term goal is an in-depth analysis of actions and mechanisms by which anesthetic agents affect ischemic myocardium. The majority of previous investigations elucidating the cardiovascular pharmacology of anesthetic agents has been conducted in acute, frequently open chest preparations, with a baseline anesthetic. Additionally, more previous work completed in vivo has involved use of experimental preparations with only a small region of ischemia. In this proposal, the effects of 3 volatile anesthetics (halothane, enflurane and isoflurane) and 2 narcotic agonists (fentanyl and sufentanil) on ischemic myocardium will be investigated in chronically instrumented dogs. This preparation offers the advantage of direct comparison of anesthetic and conscious states. Specific studies will be directed towards elucidating anesthetic actions on oxygen supply-demand balance in normal regions and in regions with various degrees of ischemia. Dose response relationships of each agent will be studied in dogs with acute or chronic occlusion of the left anterior descending coronary artery. Prior implantation of Ameroid constrictors will allow for study of each agent in myocardium with varying degrees of collateralization. In certain experiments, this will be combined with mild or severe degrees of constriction of the left circumflex coronary artery in models of multivessel coronary artery disease. Regional myocardial perfusion will be measured by radioactive microspheres and regional wall thickness determined by means of Doppler transducers implanted in normal and ischemic zones. In addition, hemodynamics, global cardiac function, regional electrical activity and myocardial oxygen consumption and lactate metabolism will be recorded in the conscious state and after administration of volatile anesthetics or narcotic agonists. The effects of these agents on protection of ischemic myocardium following acute coronary artery occlusion will also be studied. Myocardial infarct size will be measured by a histochemical staining technique. Anesthetic-induced enhancement or decrement in true coronary collateral perfusion and/or myocardial oxygen demand will be correlated with changes in systemic and coronary hemodynamics. These studies will lend insight into mechanisms whereby anesthetics produce alterations in myocardial oxygen balance and provide evidence of which anesthetic is most beneficial for ischemic myocardium.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
1R01HL036144-01A1
Application #
3350850
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1986-12-01
Project End
1990-11-30
Budget Start
1986-12-01
Budget End
1987-11-30
Support Year
1
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Medical College of Wisconsin
Department
Type
Schools of Medicine
DUNS #
073134603
City
Milwaukee
State
WI
Country
United States
Zip Code
53226
Pagel, P S; Proctor, L T; Devcic, A et al. (1998) A novel alpha 2-adrenoceptor antagonist attenuates the early, but preserves the late cardiovascular effects of intravenous dexmedetomidine in conscious dogs. J Cardiothorac Vasc Anesth 12:429-34
Farber, N E; Poterack, K A; Schmeling, W T (1997) Dexmedetomidine and halothane produce similar alterations in electroencephalographic and electromyographic activity in cats. Brain Res 774:131-41
Arkonac, B M; Kersten, J R; Wynsen, J C et al. (1996) Differential hemodynamic effects of the nitric oxide donor pirsidomine in comparison to SIN-1, nitroprusside and nitroglycerin. Pharmacology 52:92-100
Ganjoo, P; Farber, N E; Schwabe, D et al. (1996) Desflurane attenuates the somatosympathetic reflex in rats. Anesth Analg 83:55-61
Kersten, J R; Pagel, P S; Hettrick, D A et al. (1995) Dexmedetomidine partially attenuates the sympathetically mediated systemic and coronary hemodynamic effects of cocaine. Anesth Analg 80:114-21
Kersten, J R; Warltier, D C (1995) Modulation of coronary collateral angiogenesis: a canine model of neovascularization induced by chronic ischemia. J Card Surg 10:354-7
Harkin, C P; Pagel, P S; Tessmer, J P et al. (1995) Systemic and coronary hemodynamic actions and left ventricular functional effects of levosimendan in conscious dogs. J Cardiovasc Pharmacol 26:179-88
Pagel, P S; Harkin, C P; Hettrick, D A et al. (1995) Zatebradine, a specific bradycardic agent, alters the hemodynamic and left ventricular mechanical actions of levosimendan, a new myofilament calcium sensitizer, in conscious dogs. J Pharmacol Exp Ther 275:127-35
Kersten, J R; Pagel, P S; Warltier, D C (1995) Protamine inhibits coronary collateral development in a canine model of repetitive coronary occlusion. Am J Physiol 268:H720-8
Wynsen, J C; O'Brien, P D; Warltier, D C (1994) Zatebradine, a specific bradycardic agent, enhances the positive inotropic actions of dobutamine in ischemic myocardium. J Am Coll Cardiol 23:233-41

Showing the most recent 10 out of 77 publications